Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.

Next Previous
Search
Trial Profile

A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 801 (Primary) ; Cisplatin; Gemcitabine
  • Indications Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation

Most Recent Events

  • 04 Oct 2016 According to Altor BioScience Corporation media release, Status changed from active, no longer recruiting to completed.
  • 11 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2017.
  • 24 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top